There are 449 resources available
Q&A
Session: Mini Oral session 3
Resources:
Webcast
195MO - Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity
Presenter: Horst-Dieter Hummel
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
196MO - Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
Presenter: Ying Cheng
Session: Mini Oral session 3
Resources:
Abstract
197MO - Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group
Presenter: Giannis Mountzios
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Invited Discussant 195MO, 196MO and 197MO
Presenter: Jessica Menis
Session: Mini Oral session 3
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 3
Resources:
Webcast
3MO - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2
Presenter: Ryan Gentzler
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Case presentation
Presenter: Kristof Cuppens
Session: Challenges with neo-adjuvant IO
Resources:
Slides
Webcast
5MO - Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study
Presenter: Maria Rosario Garcia Campelo
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Assessing response and clinical benefit after NEOAdjuvant IO: The surgeon perspective
Presenter: Chris Dickhoff
Session: Challenges with neo-adjuvant IO
Resources:
Slides
Webcast